What are the most common side effects of ERYTHROPOIETIN?

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for ERYTHROPOIETIN. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Is ERYTHROPOIETIN the same as PROCRIT?

PROCRIT is a brand name for ERYTHROPOIETIN. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

ERYTHROPOIETIN

Q: What is ERYTHROPOIETIN used for?

ERYTHROPOIETIN (brand name PROCRIT) is a Other indicated for and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac.

Q: How does ERYTHROPOIETIN work?

ERYTHROPOIETIN works through the following mechanism: 12.1 Mechanism of Action PROCRIT stimulates erythropoiesis by the same mechanism as endogenous erythropoietin..

Other

Brand names: PROCRIT

Intravenous, Subcutaneous

Mechanism of Action

12.1 Mechanism of Action PROCRIT stimulates erythropoiesis by the same mechanism as endogenous erythropoietin.

Indications

and upon initiation

there is a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective

noncardiac

nonvascular surgery ( 1.4 ). Limitations of Use PROCRIT has not been shown to improve quality of life

fatigue

or patient well-being ( 1.5 ). PROCRIT is not indicated for use: In patients with cancer receiving hormonal agents

Contraindications

• infants
• pregnant women
• and lactating women [see Warnings and Precautions (5.9)
• Use in Specific Populations (8.1
• 8.2

FDA Warnings

5 WARNINGS AND PRECAUTIONS Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism: Using ESAs to target a hemoglobin level of greater than 11 g/dL increases the risk of serious adverse cardiovascular reactions and has not been shown to provide additional benefit ( 5
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence in Patients with Cancer ( 5
Seizures: PROCRIT increases the risk for seizures in patients with CKD ( 5
Serious Allergic Reactions: Discontinue PROCRIT and manage reactions ( 5

Known Side Effects

8 documented side effects by frequency

Fatigue

1-10%

Weakness

1-10%

Diarrhea

1-10%

Nausea

1-10%

Shortness of Breath

1-10%

Drug Not Working

0.1-1%

Vomiting

0.1-1%

Fever

0.1-1%

Community Discussions

No community discussions found for ERYTHROPOIETIN yet.

Primary sources

Every figure on this page links back to its primary source. See data sources for full provenance.

DailyMed FDA label search → ERYTHROPOIETIN openFDA label JSON → ERYTHROPOIETIN FAERS adverse-event reports → ERYTHROPOIETIN ClinicalTrials.gov → completed Phase 2+ trials of ERYTHROPOIETIN

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Intravenous, Subcutaneous